BMS-986278 Placebo

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisPulmonary Fibrosis

Phase 2

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

CompletedNCT04308681

Bristol-Myers SquibbPulmonary Fibrosis

Start: 2020-07-29End: 2023-09-22Updated: 2026-02-03

Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Active, not recruitingNCT06003426

Bristol-Myers SquibbIdiopathic Pulmonary Fibrosis

Start: 2023-09-14End: 2027-06-04Updated: 2026-03-24

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Active, not recruitingNCT06025578

Bristol-Myers SquibbProgressive Pulmonary Fibrosis

Start: 2023-10-25End: 2027-12-27Target: 1057Updated: 2026-04-23

Related Papers

Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant

Respiratory Research2026-07-15

Design and Rationale of a Phase 3 Trial for Admilparant (BMS-986278), an Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Progressive Pulmonary Fibrosis: ALOFT-PPF

American Journal of Respiratory and Critical Care Medicine2025-05-01

Design and Rationale for a Phase 3 Trial of Admilparant (BMS-986278), An Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Idiopathic Pulmonary Fibrosis: ALOFT-IPF

American Journal of Respiratory and Critical Care Medicine2025-05-01

Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.

2025-04-081 citations

Efficacy and Safety of Admilparant, an LPA <sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial

American Journal of Respiratory and Critical Care Medicine2024-10-1132 citations

RCT Abstract - BMS-986278 for progressive pulmonary fibrosis (PPF): results from a phase 2 randomized controlled trial

2023-09-094 citations

First-in-human evaluation of 18F-BMS-986327 as a novel PET tracer to assess lysophosphatidic acid receptor 1 (LPA1) target engagement in the lung

2022-09-04

LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis

Respiratory Research2022-03-1854 citations

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

BMJ Open Respiratory Research2021-12-0150 citations

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA<sub>1</sub>) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Journal of Medicinal Chemistry2021-10-2853 citations